Loading
RNK05047 is a targeted protein degrader from Ranok Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.
RNK05047 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Ranok Therapeutics (Hangzhou) Co., Ltd., in metastatic cancer. A targeted protein degrader, as described in the registry record: it tags a cancer-driving protein for destruction by the cell's own disposal system. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A targeted protein degrader, as described in the registry record: it tags a cancer-driving protein for destruction by the cell's own disposal system.
1.RNK05047 binds its target with one end and an E3 ubiquitin ligase with the other.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"RNK05047" OR ABSTRACT:"RNK05047") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RNK05047, not a curated reading list.
Shares Ranok Therapeutics (Hangzhou), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.